8-K: Bespoke Extracts Reports Q1 Growth Amid Rebranding, Outperforms Contracting Cannabis Market

Bespoke Extracts, Inc. (OTCQB: BSPK) announced its first-quarter 2025 financial results, showcasing revenue growth and reduced net loss driven by strategic rebranding to The Joint Company and new product launches, despite an overall market contraction in Colorado.

Summary

• Revenue increased to $263,159 in Q1 2025, up 1.0% from $260,428 in Q1 2024, primarily due to strong direct sales of branded pre-rolled joints and expanded joint production services.
• Gross profit improved to $110,779 in Q1 2025 from $102,581 in Q1 2024, attributed to enhanced production efficiencies.
• Operating expenses decreased to $356,117 in Q1 2025 from $405,384 in Q1 2024, reflecting lower stock-based compensation, reduced salaries, and decreased professional fees.
• Net loss was reduced to $260,521 in Q1 2025, down from $314,118 in Q1 2024.
• The company successfully rebranded as The Joint Company (TJC) in Q1 2025, scaling its white-label processing business and launching new branded products, Doobskis and Dutch Blunts.
• Daily pre-roll production increased by 32% compared to Q1 2024, enhancing competitive processing services and enabling lower-priced products.
• Total current assets decreased to $123,120 as of March 31, 2025, from $165,257 as of December 31, 2024.
• Cash decreased to $30,365 as of March 31, 2025, from $60,305 as of December 31, 2024.
• Total liabilities increased to $2,582,325 as of March 31, 2025, from $2,451,026 as of December 31, 2024.
• Total stockholders deficit increased to $(2,334,200) as of March 31, 2025, from $(2,091,938) as of December 31, 2024.

Sentiment

Score: 7

Explanation: The company demonstrated strong operational improvements, including revenue growth against a contracting market, improved gross profit, and reduced net loss, driven by successful rebranding and new product launches. However, the balance sheet shows a decrease in cash and current assets, alongside an increase in total liabilities and stockholders' deficit, which introduces a degree of financial risk despite operational successes.

Positives

• Achieved year-over-year revenue growth of 1.0% to $263,159, despite an 8.8% contraction in the broader Colorado regulated cannabis market.
• Improved gross profit to $110,779, driven by enhanced production efficiencies in pre-rolled joints.
• Reduced operating expenses by $49,267, reflecting lower stock-based compensation, salaries, and professional fees.
• Significantly reduced net loss to $260,521 from $314,118 in the prior year quarter.
• Successfully rebranded as The Joint Company (TJC) and launched new branded products (Doobskis and Dutch Blunts) which gained significant traction.
• Increased daily pre-roll production by 32% compared to Q1 2024, enhancing competitive positioning and product offerings.
• Achieved cost efficiencies in raw materials, packaging, and labor, contributing to gross margin improvements.

Negatives

• Total current assets decreased from $165,257 to $123,120, indicating a reduction in liquidity.
• Cash balance significantly decreased from $60,305 to $30,365.
• Total liabilities increased from $2,451,026 to $2,582,325.
• The total stockholders deficit worsened, increasing from $(2,091,938) to $(2,334,200).
• Higher packaging and testing costs for new product launches partially offset gross profit improvements.
• Increased marketing and sampling costs for new product launches were incurred.

Risks

• Forward-looking statements are subject to a multitude of risks and uncertainties that could cause actual results to differ materially from projections, including those set forth in the company's latest Form 10-K.

Future Outlook

The company projects revenue exceeding $385,000 for the quarter ending June 30, 2025 (Fiscal Q2 2025), compared to $278,163 in Q2 2024, driven by continued growth of FreshJoints, strong demand for Doobskis and Dutch Blunts, and expanded third-party processing services. Management expects continued improvements in manufacturing processes to support higher production volumes and consistent product quality, and enhanced production efficiencies and cost management are projected to drive higher gross margins despite increased marketing investments.

Management Comments

• Q1 2025 marked a transformative period for Bespoke Extracts as we rebranded to The Joint Company and introduced Doobskis and Dutch Blunts.
• These initiatives, combined with enhanced third-party processing capabilities, have significantly strengthened our market position and revenue potential.
• Despite an 8.8% contraction in Colorado's regulated cannabis market during the quarter ending March 31, 2025 compared to Q1 2024, we achieved year-over-year growth.
• Our improved manufacturing processes are delivering strong results, and we expect continued gross margin improvements as we scale.
• We remain committed to disciplined financial management and strategic expansion in the regulated cannabis market.

Industry Context

The company operates in the regulated cannabis markets in the United States, specifically Colorado. Its Q1 2025 performance of 1.0% revenue growth stands out against a reported 8.8% contraction in Colorado's regulated cannabis market during the same period, indicating strong internal strategic execution and product demand relative to broader industry headwinds.

Comparison to Industry Standards

• The company achieved year-over-year revenue growth of 1.0% in Q1 2025, which is notably positive given the 8.8% contraction observed in Colorado's regulated cannabis market during the same period (Q1 2025 compared to Q1 2024). This indicates the company's strategic initiatives, such as rebranding to The Joint Company and launching new products like Doobskis and Dutch Blunts, have allowed it to outperform the general market trend in Colorado.

Related Party Transactions

• The balance sheet lists 'Advances related party' of $66,872 as of March 31, 2025 and December 31, 2024.
• The balance sheet lists 'Note Payable related party' of $849,500 as of March 31, 2025 and December 31, 2024.

Stakeholder Impact

• Shareholders: Positive operational performance (revenue growth, reduced loss) and strategic initiatives could lead to increased value, but increasing liabilities and a growing deficit present financial concerns.
• Employees: Operating expenses reflect reduced salaries, indicating potential impact on employee compensation.
• Customers/Dispensaries: Benefit from new branded products (Doobskis, Dutch Blunts), continued growth of FreshJoints, and competitive pricing due to enhanced production efficiencies and expanded third-party processing services.
• Suppliers: Potential for increased demand for raw materials and packaging due to higher production volumes, though cost efficiencies are being sought.
• Creditors: Increased total liabilities and a growing stockholders' deficit may raise concerns regarding the company's financial leverage and ability to service debt.

Next Steps

• Continue expanding market share and optimizing operations for sustainable, long-term growth.
• Explore expansion of The Joint Company (TJC) into other state-regulated cannabis markets.
• Focus on continued improvements in manufacturing processes to support higher production volumes and consistent product quality.
• Drive higher gross margins through enhanced production efficiencies and cost management, despite increased marketing investments for new product launches.

Key Dates

Recommendation

Keywords

cannabis, regulated cannabis market, pre-rolled joints, marijuana-infused products, The Joint Company, Bespoke Extracts, Colorado cannabis, white-label processing, Doobskis, Dutch Blunts, financial results, Q1 2025, revenue growth, net loss reduction, strategic rebranding